natgillin/translations-raw huggingface dataset:
The risk of recurrence was thus reduced by approximately 89% as compared with placebo (hazard ratio = 0.113 [0.049-0.264]). 
Rizik od recidiva bolesti je smanjen za otprilike 89% u usporedbi s placebom (omjer rizika = 0,113 [0,049-0,264]).
If you have any questions about how Imatinib Teva B.V. works or why this medicine has been prescribed for you, ask your doctor. 
Ako imate bilo kakvih pitanja o tome na koji način djeluje Imatinib Teva B.V., ili zašto je taj lijek Vama propisan, obratite se svom liječniku.
In 61 of these 117 patients FIP1L1-PDGFRα fusion kinase was identified. 
U 61 od tih 117 bolesnika identificirana je fuzijska kinaza FIP1L1-PDGFRα.
The effect of stopping treatment after achieving a response has not been investigated. 
Učinak prekida liječenja nakon postizanja odgovora nije ispitivan.
Women of childbearing potential must be advised to use effective contraception during treatment. 
Žene reproduktivne dobi treba savjetovati da koriste učinkovitu kontracepciju tijekom liječenja.
At the time of analysis, the treatment duration was a median of 7 months (7 days to 13 months). 
U vrijeme provođenja analize, medijan trajanja liječenja iznosio je 7 mjeseci (7 dana do 13 mjeseci).
Name and address of the manufacturers responsible for batch release Teva Czech Industries s.r.o. 
Naziv i adresa proizvođača odgovornih za puštanje serije lijeka u promet Teva Czech Industries s.r.o.
Store below 30°C 
Čuvati na temperaturi ispod 30°C.
These patients ranged in age from 18 to 83 years old and had a pathologic diagnosis of Kit-positive malignant GIST that was unresectable and/or metastatic. 
Dob se tih bolesnika kretala od 18 do 83 godine, a imali su patološku dijagnozu Kit-pozitivnog malignog GIST-a koji je bio inoperabilan i/ili metastatski.
The median time of follow-up was 54 months (from date of randomisation to data cut-off), with a total of 83 months between the first patient randomised and the cut-off date. 
Medijan vremena praćenja bio je 54 mjeseca (od datuma randomizacije do završetka prikupljanja podataka), pri čemu je od randomizacije prvog bolesnika do završetka prikupljanja podataka prošlo 83 mjeseca.
- If you are being treated for HES/CEL: 
Ako se liječite zbog HES/KEL-a:
Treatment with imatinib may be interrupted or the dose may be reduced, as recommended in section 
Liječenje imatinibom može se prekinuti ili se doza može smanjiti, kao što je preporučeno u dijelu 4.2.
Do not stop taking Imatinib Teva B.V. unless your doctor tells you to. 
Nemojte prestati uzimati Imatinib Teva B.V., osim ako Vam to ne kaže liječnik.
C/C, n. 4, Poligono Industrial Malpica 
4, Poligono Industrial Malpica
Check with your doctor or pharmacist if you are 
Provjerite s liječnikom ili ljekarnikom ako niste sigurni.
Five (5) patients responded, 3 completely and 2 partially. 
5 bolesnika je imalo odgovor, 3 kompletni i 2 parcijalni.
If it is used during pregnancy, the patient must be informed of the potential risk to the foetus. 
Ako se primjenjuje tijekom trudnoće, bolesnica mora biti informirana o potencijalnom
In children and adolescents, Imatinib Teva B.V. can be used in different phases of the disease (chronic, accelerated phase and blast crisis). 
U djece i adolescenata, Imatinib Teva B.V. se može koristiti u različitim fazama bolesti (kronična, ubrzana faza i blastična kriza).
In clinical trials, there was an increased incidence of these events in older people and those with a prior history of cardiac disease. 
U kliničkim je ispitivanjima zabilježena povećana incidencija tih događaja u starijih osoba te u onih s anamnezom srčanih bolesti.
The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1). 
Iskustvo s imatinibom u bolesnika s MDS/MPB-om povezanim s preuredbom gena za PDGFR je vrlo ograničeno (vidjeti dio 5.1).
Following oral administration in healthy volunteers, the t½ was approximately 18 h, suggesting that oncedaily dosing is appropriate. 
Nakon peroralne primjene u zdravih dobrovoljaca, t½ bilo je oko 18 h, što navodi na zaključak da je doziranje jedanput na dan primjereno.
For CML and GIST, your doctor may prescribe a higher or lower dose depending on how you respond to treatment. 
Liječnik Vam za KML i GIST može propisati višu ili nižu dozu, ovisno o tome kako reagirate na liječenje.
The most important changes included cardiac hypertrophy and dilatation, leading to signs of cardiac insufficiency in some animals. 
Najvažnije promjene uključivale su srčanu hipertrofiju i dilataciju, što je, u nekih životinja, dovelo do znakova srčane
Figure 2 Kaplan-Meier estimates for overall survival (ITT population) 
Kaplan-Meierova procjena ukupnog preživljenja (ITT populacija)
The long-term effects of prolonged treatment with imatinib on growth in children are unknown. 
Nisu poznati dugoročni učinci produljene terapije imatinibom na rast djece.
Based on preliminary population pharmacokinetic analysis in GIST patients, there were three variables (albumin, WBC and bilirubin) found to have a statistically significant relationship with imatinib pharmacokinetics. 
Na temelju preliminarne analize populacijske farmakokinetike u bolesnika s GIST-om, utvrđeno je da tri varijable (albumin, WBC i bilirubin) imaju statistički značajan odnos s farmakokinetikom imatiniba.
When the response rate is calculated from patients with at least one valid assessment, the response rate for CHR, CCyR and MR was 20/22 (90.9%), 9/9 (100%) and 11/17 
Kad se stopa odgovora računa u bolesnika s barem jednom valjanom procjenom, stopa odgovora za CHR, CCyR i MR bila je 20/22 (90,9%), 9/9 (100%) odnosno 11/17 (64,7%).
Limited data exist on the effect of dose increases from 400 mg to 600 mg or 800 mg in patients progressing at the lower dose (see section 5.1). 
Postoje ograničeni podaci o učinku povećanja doze s 400 mg na 600 mg ili 800 mg u bolesnika u kojih do progresije dolazi uz nižu dozu (vidjeti dio 5.1).
Myeloid blast crisis: 260 patients with myeloid blast crisis were enrolled. 
Mijeloična blastična kriza: ispitivanje je uključeno 260 bolesnika s mijeloičnom blastičnom krizom.
Three patients presented a complete haematological response (CHR) and one patient experienced a partial haematological response (PHR). 
Tri bolesnika postigla su kompletni hematološki odgovor (CHR), a jedan bolesnik parcijalni hematološki odgovor (PHR).
Paediatric use: There is no experience in children with CML below 2 years of age and with Ph+ALL below 1 year of age (see section 5.1). 
Primjena u pedijatriji: Ne postoji iskustvo kod djece s KML-om mlađe od 2 godine i djece mlađe od 1 godine s Ph+ ALL-om (vidjeti dio 5.1).
Patients should be tested for HBV infection before initiating treatment with Imatinib Teva B.V. 
Bolesnike je potrebno testirati na infekciju HBV-om prije početka liječenja Imatinibom Teva B.V.
While you are taking Imatinib Teva B.V. your doctor will regularly check whether the medicine is working. 
Dok uzimate Imatinib Teva B.V., liječnik će redovito pratiti da li lijek djeluje.
The median time to progression in the overall population of 411 patients with relapsed/refractory Ph+ ALL ranged from 2.6 to 3.1 months, and median overall survival in the 401 evaluable patients ranged from 4.9 to 9 months. 
Medijan vremena do progresije u ukupnoj populaciji od 411 bolesnika s recidivirajućom ili refraktornom Ph+ ALL kretao se od 2,6 do 3,1 mjesec, a medijan ukupnog preživljenja kod 401 evaluiranog bolesnika kretao se od 4,9 do
Imatinib Teva B.V. can reduce the number of white blood cells, so you might get infections more easily. 
B.V. može smanjiti broj bijelih krvnih stanica, pa možete lakše dobiti infekciju.
In adults the dose should be reduced from 400 to 300 mg or from 600 to 400 mg, or from 800 mg to 600 mg, and in children from 340 to 260 mg/m2/day. 
Dozu u odraslih treba sniziti s 400 na 300 mg ili s 600 na 400 mg, ili s 800 mg na 600 mg, a u djece s 340 na 260 mg/m2/dan.
In clinical trials in CML, drug discontinuation for drug-related adverse reactions was observed in 2.4% of newly diagnosed patients, 4% of patients in late chronic phase after failure of interferon therapy, 4% of patients in accelerated phase after failure of interferon therapy and 5% of blast crisis patients after failure of interferon therapy. 
U kliničkim ispitivanjima KML-a ukidanje lijeka zbog nuspojava povezanih s njegovom primjenom zapaženo je u 2,4% novodijagnosticiranih bolesnika, 4% bolesnika u kasnoj kroničnoj fazi nakon neuspjeha terapije interferonom, 4% bolesnika u ubrzanoj fazi nakon neuspjeha terapije interferonom i 5% bolesnika u blastičnoj krizi nakon neuspjeha terapije interferonom.
When female rats were dosed 14 days prior to mating and through to gestational day 6, there was no effect on mating or on number of pregnant females. 
14 dana prije parenja pa sve do 6. dana gestacije, nije bilo učinka na parenje ili na broj skotnih ženki.
An additional four HES patients were found to be FIP1L1-PDGFRα-positive in other 3 published reports. 
Dodatna četiri bolesnika s HES-om bila su pozitivna za FIP1L1-PDGFRα u ostala 3 objavljena slučaja.
• Muscle weakness and spasms with an abnormal heart rhythm (signs of changes in the amount of 
• Mišićna slabost i grčevi mišića s abnormalnim srčanim ritmom (znakovi promjena količine
C/C, n. 4, Poligono Industrial Malpica, 50016 Zaragoza 
4, Poligono Industrial Malpica, 50016 Zaragoza
Total bilirubin: >1.5-3.0 ULN AST: any 
Ukupni bilirubin: >1,5-3,0 GGN AST: bilo koja vrijednost
• The adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. 
• Adjuvantno liječenje odraslih bolesnika s visokim rizikom od recidiva bolesti nakon resekcije Kit (CD117)-pozitivnog GIST-a.
Your doctor will discuss with you the possible risks of taking Imatinib Teva B.V. during pregnancy. 
Liječnik će Vam objasniti moguće rizike od uzimanja Imatiniba Teva B.V. tijekom trudnoće.
Lymphoid blast crisis: a limited number of patients were enrolled in phase I studies (n=10). 
Limfatična blastična kriza: u ispitivanjima faze I uključen je ograničeni broj bolesnika (n=10).
• Adult patients with Ph+ CML in blast crisis. 
• Odraslih bolesnika s Ph+ KML-om u blastičnoj krizi.
Overall hazard ratio (95% CI)* 
Ukupni omjer rizika (95% CI) *
In the study in patients with unresectable and/or metastatic GIST, grade 3 and 4 anaemia was reported in 5.4% and 0.7% of patients, respectively, and may have been related to gastrointestinal or intra-tumoural bleeding in at least some of these patients. 
U ispitivanju s bolesnicima s inoperabilnim i/ili metastazirajućim GIST-om, anemija 3. i 4. stupnja zabilježena je u 5,4% odnosno 0,7% bolesnika i mogla je biti povezana s gastrointestinalnim ili intratumorskim krvarenjem barem u nekih od tih bolesnika.
- If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby ask your doctor for advice before taking this medicine. 
Ako ste trudni ili dojite, mislite da biste mogli biti trudni ili planirate imati dijete, obratite se svom liječniku za savjet prije nego uzmete ovaj lijek.
The decreases in white blood cell (WBC) and neutrophil counts occurred mainly during the first six weeks of therapy, with values remaining relatively stable thereafter. 
Do smanjenja broja leukocita (Lkc) i broja neutrofila uglavnom je došlo tijekom prvih šest tjedana terapije, a vrijednosti su nakon toga ostale relativno
Teva Pharmaceuticals Polska Sp. z o.o. 
Teva Operations Poland Sp. z o.o. ul.
No specific dose recommendation is necessary in older people. 
Za starije osobe nije potrebna posebna preporuka doziranja.
In adult patients, Imatinib Teva B.V. is intended for use in the most advanced phase of the disease (blast crisis). 
U odraslih bolesnika, Imatinib Teva B.V. je namijenjen za liječenje najuznapredovanijih faza bolesti (blastična kriza).
Frequency categories are defined using the following convention: very common (≥1/10), common 
Kategorije učestalosti se definiraju kao: vrlo često (≥1/10), često
At the time of the original analysis, three of the four patients with detected PDGFR gene rearrangements developed haematological response (2 CHR and 1 PHR). 
U vrijeme početne analize, kod tri od četiri bolesnika s utvrđenom preuredbom gena za PDGFR razvio se hematološki odgovor (2 CHR i 1 PHR).
At one year the overall RFS was significantly better for imatinib (97.7%) vs. placebo (82.3%), (p<0.0001). 
Nakon jedne godine ukupno preživljenje bez recidiva bolesti bilo je značajno bolje za imatinib (97,7%) u odnosu na placebo (82,3%), (p<0,0001).
The comparison of AUC(0-24) on day 8 and day 1 at the 340 mg/m2/day dose level revealed a 1.7-fold drug accumulation after repeated once-daily dosing. 
Usporedba AUC(0-24) na dan 8 i dan 1 uz dozu od 340 mg/m2/dan otkrila je 1,7 puta veću akumulaciju lijeka nakon ponovljenog
Median time to response was 13 weeks (95% C.I. 
Medijan vremena do odgovora bio je 13 tjedana (95% CI 12-23).
Carriers of HBV who require treatment with Imatinib Teva B.V. should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy (see section 4.8). 
Nositelje virusa HBV kojima je potrebno liječenje Imatinibom Teva B.V. potrebno je pozorno nadzirati radi utvrđivanja eventualnih znakova i simptoma aktivne infekcije HBV-om tijekom terapije te nekoliko mjeseci nakon završetka terapije (vidjeti dio 4.8).
Therefore, caution should be recommended when driving a car 
Stoga se preporučuje oprez pri upravljanju vozilima ili radu sa strojevima.
Imatinib Teva B.V. may do the same to some other medicines. 
Imatinib Teva B.V. može to isto napraviti nekim drugim lijekovima.
There are no controlled trials in paediatric patients with c-Kit positive GIST. 
Nema kontroliranih ispitivanja u pedijatrijskih bolesnika s c-Kit pozitivnim GIST-om.
When needed, discontinuation of Imatinib Teva B.V. treatment may be considered. 
Ukoliko je potrebno, može se razmotriti prekid liječenja Imatinibom Teva B.V.
You should wash your hands immediately after opening the capsules. 
Operite ruke odmah nakon
In two clinical studies (study B2222 and an intergroup study S0033) the daily dose of imatinib was escalated to 800 mg in patients progressing at the lower daily doses of 400 mg or 600 mg. 
U dvije kliničke studije (studija B2222 i intergrupna studija S0033) dnevna doza imatiniba je povećana do 800 mg u bolesnika kod kojih je došlo do progresije pri nižim dnevnim dozama od 400
- If you are a woman who is pregnant or might get pregnant and are trying to open the capsules, you should handle the contents with caution in order to avoid skin-eye contact or inhalation. 
Ako ste trudni ili možete ostati trudni, a pokušavate otvoriti kapsule, morate pažljivo rukovati sa sadržajem te izbjegavati kontakt s kožom i očima ili inhaliranje.
• Severe headache, weakness or paralysis of limbs or face, difficulty speaking, sudden loss of consciousness (signs of nervous system problems such as bleeding or swelling in skull/brain). 
• teška glavobolja, slabost ili paraliza udova ili lica, otežan govor, iznenadni gubitak svijesti (znakovi problema živčanog sustava kao što su krvarenje ili oticanje u lubanji/mozgu).
Thereafter, treatment can be resumed as appropriate depending on the initial severity 
Nakon toga se liječenje može nastaviti ovisno o početnoj
- The tablet coating is made of polyvinyl alcohol partially hydrolysed, macrogol, iron oxide yellow 
- Ovojnica tablete sastoji se od polivinilnog alkohola djelomično hidroliziranog, makrogola,
Ileus/intestinal obstruction*, gastrointestinal perforation*, diverticulitis*, gastric antral vascular ectasia (GAVE)* 
divertikulitis*, gastrična antralna vaskularna ektazija (GAVE)*
Blood creatinine increased, blood creatine phosphokinase increased, blood lactate dehydrogenase increased, blood alkaline phosphatase 
Povišen kreatinin u krvi, povišena kreatin-fosfokinaza u krvi, povišena laktatdehidrogenaza u krvi, povišena alkalna fosfataza u krvi
The total daily dose in children must not exceed 800 mg with CML and 600 mg with Ph+ALL. 
Ukupna dnevna doza u djece i adolescenata ne smije prijeći 800 mg kod KML-a i 600 mg kod Ph+ALL-a.
In this patient population, the presence of hepatic metastases could potentially lead to hepatic insufficiency and reduced metabolism. 
U toj bi populaciji bolesnika prisutnost metastaza u jetri mogla potencijalno dovesti do jetrene insuficijencije i
Imatinib in combination with chemotherapy induction (see Table 3) resulted in a complete haematological response rate of 93% (147 out of 158 evaluable patients) and in a major cytogenetic response rate of 90% (19 out of 21 evaluable patients). 
Imatinib u kombinaciji s indukcijskom kemoterapijom (vidjeti Tablicu 3) rezultira postizanjem stope kompletnog hematološkog odgovora od 93% (147 od 158 evaluiranih bolesnika) i stope velikog citogenetskog odgovora od 90% (19 od 21 evaluiranog bolesnika).
Study 0102 38-month data Myeloid blast crisis (n=260) 
Studija 0102 38-mjesečni podaci Mijeloična blastična kriza
They may increase or decrease the effect of Imatinib Teva B.V., either leading to increased side effects or making Imatinib Teva B.V. less effective. 
Oni mogu povećati ili smanjiti učinak Imatiniba Teva B.V. bilo povećanjem nuspojava ili smanjenjem učinka Imatiniba Teva B.V.
• Chest pain, irregular heart rhythm (signs of heart problems). 
• Bol u prsnom košu, nepravilan srčani ritam (znakovi srčanih problema).
1800 to 3200 mg (as high as 3200 mg daily for 6 days): Weakness, myalgia, increased creatine phosphokinase, increased bilirubin, gastrointestinal pain. 
1800 mg do 3200 mg (najviše 3200 mg na dan tijekom 6 dana): slabost, mialgija, povišenje vrijednosti kreatinin fosfokinaze, povišenje vrijednosti bilirubina, bol u trbuhu.
What you need to know before you take Imatinib Teva B.V. 
Što morate znati prije nego počnete uzimati Imatinib Teva B.V.
Imatinib treatment induces a rapid response in newly diagnosed paediatric CML patients with a CHR of 78% after 8 weeks of therapy. 
Liječenje imatinibom izazvalo je brzi odgovor pedijatrijskih bolesnika s novodijagnosticiranim KML-om sa CHR-om od 78% nakon 8 tjedana terapije.
Keep taking Imatinib Teva B.V. every day for as long as your doctor tells you. 
Imatinib Teva B.V. nastavite uzimati svaki dan onoliko dugo koliko Vam je liječnik rekao.
• The treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST). 
• Liječenje odraslih bolesnika s Kit (CD 117) pozitivnim inoperabilnim i/ili metastazirajućim malignim gastrointestinalnim stromalnim tumorima (GIST).
The primary endpoint of the study was recurrence-free survival (RFS), defined as the time from date of randomisation to the date of recurrence or death from any cause. 
Primarni ishod ispitivanja bio je preživljenje bez recidiva bolesti, definirano kao vrijeme od datuma randomizacije do datuma recidiva ili smrti zbog bilo kojeg uzroka.
After resection of primary GIST, patients were randomised to one of the two arms: imatinib at 400 mg/day or matching placebo for one year. 
Nakon resekcije primarnog GIST-a, bolesnici su randomizirani u jedan od dva kraka: imatinib 400 mg/dan ili odgovarajući placebo tijekom jedne godine.
In patients with GIST steady-state exposure was 1.5-fold higher than that observed for CML patients for the same dosage (400 mg daily). 
U bolesnika s GIST-om izloženost u stanju dinamičke ravnoteže bila je 1,5 puta veća od one koja je zapažena u bolesnika s KML-om uz isto doziranje (400 mg na dan).
Imatinib Teva B.V. inhibits the growth of these cells in a certain subtype of these diseases. 
Imatinib Teva B.V. inhibira rast ovih stanica u određenoj podvrsti ovih bolesti.
Seventeen (17) patients with GIST (with or without Kit and PDGFR mutations) were reported in 7 publications. 
U 7 publikacija zabilježeno je sedamnaest (17) bolesnika s GIST-om (sa ili bez Kit ili PDFGR mutacija).
Events that have been reported at different dose ranges are as follows: 
Zabilježeni su sljedeći događaji u različitim
The content of the capsule is white to light yellow granulated powder. 
Sadržaj kapsule je granulirani prašak bijele
Patients with cardiac disease, risk factors for cardiac failure or history of renal failure should be monitored carefully, and any patient with signs or symptoms consistent with cardiac or renal failure should be evaluated 
Bolesnike sa srčanom bolešću, faktorom rizika za zatajenje srca ili ranijim zatajenjem bubrega treba pažljivo pratiti, a svakog bolesnika sa znakovima ili simptomima koji ukazuju na zatajenje srca ili bubrega treba obraditi i liječiti.
The effect of stopping treatment after the achievement of a complete cytogenetic response has not been 
Učinak prekida liječenja nakon postizanja potpunog citogenetskog odgovora nije ispitivan.
- if you are allergic to imatinib or any of the other ingredients of this medicine (listed in section 6). 
Nemojte uzimati Imatinib Teva B.V.: - ako ste alergični na imatinib ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
Other medicines and Imatinib Teva B.V. 
Drugi lijekovi i Imatinib Teva B.V.
NEL Same criteria as for CHR but ANC ≥ 1 x 109/l and platelets ≥ 20 x 109/l RTC < 15% blasts BM and PB, < 30% blasts+promyelocytes in BM and PB, < 20% basophils in PB, no extramedullary disease other than spleen and liver. 
NEL Isti kriteriji kao za CHR, ali je ABN ≥1 x 109/l, a trombociti ≥20 x 109/l RTC <15% blasta u KS i PK, <30% blasta+promijelocita u KS i PK, <20% bazofila u PK, nema ekstramedularne bolesti osim u slezeni i jetri
The ages of these patients ranged from 18 to 91 years. 
Dob tih bolesnika se kretala od 18 do 91 godine.
Hepatic insufficiency: Imatinib is mainly metabolised through the liver. 
Insuficijencija jetre: Imatinib se većinom metabolizira preko jetre.
Patients were included who had a histological diagnosis of primary GIST expressing Kit protein by immunochemistry and a tumour size ≥ 3 cm in maximum dimension, with complete gross resection of primary GIST within 14-70 days prior to registration. 
Uključeni bolesnici imali su histološku dijagnozu primarnog GIST-a s imunokemijski dokazanom ekspresijom Kit proteina i veličinom tumora ≥3 cm u najvećem promjeru, uz potpunu makroskopsku resekciju primarnog GIST-a unutar 14-70 dana prije uključivanja u ispitivanje.
If either is abnormal, follow-up with a cardiology specialist and the prophylactic use of systemic steroids (1-2 mg/kg) for one to two weeks concomitantly with imatinib should be considered at the initiation of therapy. 
Ako je bilo što od navedenog abnormalno, na početku terapije je potrebno razmisliti o profilaktičkoj primjeni sistemskih steroida (1-2 mg/kg) tijekom jednog do dva tjedna istodobno uz imatinib te redovitim kardiološkim
Caution should be used when taking imatinib with protease inhibitors, azole antifungals, certain macrolides 
Potreban je oprez kada se imatinib uzima s inhibitorima proteaze, azolnim antimikoticima,
One 3-year-old male exposed to a single dose of 400 mg experienced vomiting, diarrhoea and anorexia and another 3-year-old male exposed to a single dose of 980 mg experienced decreased white blood cell count 
Kod jednog trogodišnjeg dječaka izloženog jednokratnoj dozi od 400 mg došlo je do povraćanja, proljeva i anoreksije, dok je kod drugog trogodišnjeg dječaka izloženog jednokratnoj dozi od 980 mg došlo do smanjenog broja leukocita i proljeva.
Imatinib administration to patients without the genetic translocation generally results in no 
Primjena imatiniba bez genetske translokacije obično ne rezultira poboljšanjem.
In the adjuvant setting, imatinib was investigated in a multicentre, double-blind, long-term, placebocontrolled phase III study (Z9001) involving 773 patients. 
U sklopu adjuvantnog liječenja, imatinib je ispitivan u multicentričnom, dvostrukoslijepom, dugotrajnom placebo kontroliranom ispitivanju faze III (Z9001) koje je uključivalo 773 bolesnika.
Imatinib Teva B.V. may do the same to some other 
Imatinib Teva B.V. može to isto napraviti nekim drugim
The plasma protein binding of the N-demethylated metabolite is similar to that of the parent 
Vezanje N-demetiliranog metabolita za bjelančevine plazme je slično onom
- Gastrointestinal stromal tumours (GIST). 
- Gastrointestinalnih stromalnih tumora (GIST).